While the UK Supreme Court’s opinion in Actavis v Eli Lilly is a step towards a more continental approach, there remain areas of divergence. Daan de Lange and Boukje van der Maazen provide a Netherlands perspective
Canada’s new drug and biosimilar patent linkage system will fundamentally change the nature of proceedings. J Bradley White and Nathaniel Lipkus of Osler Hoskin & Harcourt discuss key changes of interest to life sciences companies
